The combination of the compound NOV202 and PARP inhibitors have shown very promising synergistic antitumoral effects in several tumour models. The combination of NOV202 and several PARP inhibitors on the market have shown improved efficacy compared to any of the pharmaceuticals given alone. Examples of preclinical cancer models used are models for ovarian-, pancreatic- and prostate cancer.